| NCT ID | NCT05848622 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of North Carolina, Chapel Hill |
| Condition | Anterior Cruciate Ligament Injuries |
| Study Type | INTERVENTIONAL |
| Enrollment | 70 participants |
| Start Date | 2023-06-13 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 70 participants in total. It began in 2023-06-13 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine the effects of real-time gait biofeedback delivered over a 6-week period on early markers of FastOA and conduct 6-week and 6-month follow-up assessments in anterior cruciate ligament reconstructed patients.
Eligibility Criteria
Inclusion Criteria: * Have completed all other formal physical therapy * Are between the ages of 16 and 35 * Underwent an anterior cruciate ligament reconstruction (ACLR) between 6 and 60 months prior to enrollment * Demonstrate underloading during gait (vGRF- impact peak \<1.12 x BW) Exclusion Criteria: * A multiple ligament surgery (i.e., PCL) * A lower extremity fracture (i.e., displaced tibial plateau fracture) * Knee osteoarthritis
Contact & Investigator
Brian Pietrosimone, PhD
PRINCIPAL INVESTIGATOR
University of North Carolina, Chapel Hill
Frequently Asked Questions
Who can join the NCT05848622 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 35 Years, studying Anterior Cruciate Ligament Injuries. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05848622 currently recruiting?
Yes, NCT05848622 is actively recruiting participants. Contact the research team at favoreto@med.unc.edu for enrollment information.
Where is the NCT05848622 trial being conducted?
This trial is being conducted at Chapel Hill, United States.
Who is sponsoring the NCT05848622 clinical trial?
NCT05848622 is sponsored by University of North Carolina, Chapel Hill. The principal investigator is Brian Pietrosimone, PhD at University of North Carolina, Chapel Hill. The trial plans to enroll 70 participants.